{"id":34164,"date":"2025-05-26T17:00:40","date_gmt":"2025-05-26T09:00:40","guid":{"rendered":"https:\/\/flcube.com\/?p=34164"},"modified":"2025-05-26T17:00:40","modified_gmt":"2025-05-26T09:00:40","slug":"walvax-biotechnology-secures-exclusive-rights-to-notitias-gut-microbiota-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34164","title":{"rendered":"Walvax Biotechnology Secures Exclusive Rights to Notitia’s Gut Microbiota Therapy"},"content":{"rendered":"\n

China’s Walvax Biotechnology Co., Ltd (SHE: 300142<\/a>) announced an exclusive sublicense agreement with US-based Notitia Biotechnologies, a company specializing in microbiome-targeted biotherapeutics. This collaboration grants Walvax exclusive rights to develop, manufacture, and commercialize Notitia’s proprietary gut microbiota therapy in mainland China, Hong Kong, and Macau for disease-specific populations.<\/p>\n\n\n\n

Technology and Platforms<\/strong>
The gut microbiota therapy platform, originally licensed from Rutgers University, integrates three core technologies: core microbiota analysis, targeted microbiota transplantation, and nutritional formulation. This comprehensive approach offers broad applications in disease diagnosis, treatment prediction, inflammatory disease management, and chronic disease intervention.<\/p>\n\n\n\n

Financial Terms and Commitments<\/strong>
Under the terms of the agreement, Walvax will make an upfront payment of USD 1 million to Notitia. Additional payments will be tied to development and sales milestones, along with long-term royalties of 6.5% of net sales.-Fineline Info & Tech<\/a><\/p>\n\n\n\n